Iain B Mcinnes

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5488448/publications.pdf

Version: 2024-02-01

134 papers	25,739 citations	36303 51 h-index	17592 121 g-index
141 all docs	141 docs citations	141 times ranked	27220 citing authors

#	Article	IF	Citations
1	The Pathogenesis of Rheumatoid Arthritis. New England Journal of Medicine, 2011, 365, 2205-2219.	27.0	4,200
2	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Annals of the Rheumatic Diseases, 2017, 76, 960-977.	0.9	3,366
3	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Annals of the Rheumatic Diseases, 2020, 79, 685-699.	0.9	1,860
4	Rheumatoid arthritis. Nature Reviews Disease Primers, 2018, 4, 18001.	30.5	1,441
5	COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovascular Research, 2020, 116, 1666-1687.	3.8	1,074
6	Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). European Journal of Immunology, 2019, 49, 1457-1973.	2.9	766
7	Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2015, 386, 1137-1146.	13.7	722
8	Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-Î± production in rheumatoid arthritis. Nature Medicine, 1997, 3, 189-195.	30.7	711
9	Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet, The, 2013, 382, 780-789.	13.7	688
10	Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. New England Journal of Medicine, 2015, 373, 1329-1339.	27.0	629
11	EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Annals of the Rheumatic Diseases, 2020, 79, 700.1-712.	0.9	609
12	Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Annals of the Rheumatic Diseases, 2014, 73, 990-999.	0.9	576
13	Golimumab, a new human tumor necrosis factor Î± antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twentyâ€fourâ€“week efficacy and safety results of a randomized, placeboâ€controlled study. Arthritis and Rheumatism, 2009, 60, 976-986.	6.7	547
14	Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet, The, 2013, 382, 1705-1713.	13.7	518
15	Guidelines for the use of flow cytometry and cell sorting in immunological studies[*]. European Journal of Immunology, 2017, 47, 1584-1797.	2.9	505
16	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Annals of the Rheumatic Diseases, 2018, 77, 3-17.	0.9	484
17	The role of interleukinâ€“15 in Tâ€“cell migration and activation in rheumatoid arthritis. Nature Medicine, 1996, 2, 175-182.	30.7	463
18	Selective Expression and Functions of Interleukin 18 Receptor on T Helper (Th) Type 1 but not Th2 Cells. Journal of Experimental Medicine, 1998, 188, 1485-1492.	8.5	330

#	Article	IF	Citations
19	Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Annals of the Rheumatic Diseases, 2014, 73, 349-356.	0.9	308
20	Cytokines as Therapeutic Targets in Rheumatoid Arthritis and Other Inflammatory Diseases. Pharmacological Reviews, 2015, 67, 280-309.	16.0	266
21	Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Annals of the Rheumatic Diseases, 2014, 73, 1000-1006.	0.9	255
22	Rheumatoid arthritis and depression: an inflammatory perspective. Lancet Psychiatry,the, 2019, 6, 164-173.	7.4	238
23	Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nature Reviews Rheumatology, 2013, 9, 513-523.	8.0	212
24	Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet, The, 2020, 395, 1126-1136.	13.7	206
25	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2020, 79, 760-770.	0.9	205
26	A Novel Therapeutic Approach Targeting Articular Inflammation Using the Filarial Nematode-Derived Phosphorylcholine-Containing Glycoprotein ES-62. Journal of Immunology, 2003, 171, 2127-2133.	0.8	196
27	Artery Tertiary Lymphoid Organs Control Aorta Immunity and Protect against Atherosclerosis via Vascular Smooth Muscle Cell Lymphotoxin Î² Receptors. Immunity, 2015, 42, 1100-1115.	14.3	179
28	Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. Lancet, The, 2020, 395, 1496-1505.	13.7	178
29	Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial. Annals of the Rheumatic Diseases, 2016, 75, 1043-1050.	0.9	167
30	Reframing Immune-Mediated Inflammatory Diseases through Signature Cytokine Hubs. New England Journal of Medicine, 2021, 385, 628-639.	27.0	156
31	Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 72, 1445-1452.	0.9	149
32	Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis. New England Journal of Medicine, 2021, 384, 1227-1239.	27.0	143
33	Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2). Annals of the Rheumatic Diseases, 2016, 75, 1984-1988.	0.9	131
34	Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. Lancet, The, 2020, 395, 427-440.	13.7	122
35	Metabolic Profiling Predicts Response to Antiâ€“Tumor Necrosis Factor Î± Therapy in Patients With Rheumatoid Arthritis. Arthritis and Rheumatism, 2013, 65, 1448-1456.	6.7	121
36	Spinal cord oligodendrocyteâ€derived alarmin ILâ€33 mediates neuropathic pain. FASEB Journal, 2016, 30, 54-65.	0.5	121

#	Article	IF	Citations
37	Managing rheumatic and musculoskeletal diseases â€" past, present and future. Nature Reviews Rheumatology, 2017, 13, 443-448.	8.0	117
38	Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). Arthritis Research and Therapy, 2018, 20, 47.	3.5	117
39	Back to the future: oral targeted therapy for RA and other autoimmune diseases. Nature Reviews Rheumatology, 2013, 9, 173-182.	8.0	106
40	Immune-mediated inflammatory disease therapeutics: past, present and future. Nature Reviews Immunology, 2021, 21, 680-686.	22.7	106
41	MicroRNA-155 influences B-cell function through PU.1 in rheumatoid arthritis. Nature Communications, 2016, 7, 12970.	12.8	97
42	MicroRNA-155 regulates monocyte chemokine and chemokine receptor expression in Rheumatoid Arthritis. Rheumatology, 2016, 55, 2056-2065.	1.9	84
43	<scp>IL</scp>â€33/<scp>ST</scp>2 signalling contributes to carrageeninâ€induced innate inflammation and inflammatory pain: role of cytokines, endothelinâ€1 and prostaglandin <scp>E</scp>₂. British Journal of Pharmacology, 2013, 169, 90-101.	5.4	81
44	Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials. Annals of the Rheumatic Diseases, 2021, 80, 185-193.	0.9	79
45	Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study. Journal of Rheumatology, 2016, 43, 1713-1717.	2.0	77
46	Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol. Trials, 2019, 20, 429.	1.6	77
47	The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis. Rheumatology, 2019, 58, 197-205.	1.9	68
48	Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2017, 76, 1949-1952.	0.9	63
49	In vivo multiplex molecular imaging of vascular inflammation using surface-enhanced Raman spectroscopy. Theranostics, 2018, 8, 6195-6209.	10.0	56
50	Tumour necrosis factor Â blockade reduces circulating N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis: results from a prospective cohort study. Annals of the Rheumatic Diseases, 2010, 69, 1281-1285.	0.9	53
51	Inducing Experimental Arthritis and Breaking Self-Tolerance to Joint-Specific Antigens with Trackable, Ovalbumin-Specific T Cells. Journal of Immunology, 2004, 173, 151-156.	0.8	52
52	Tightening Up? Impact of Musculoskeletal Ultrasound Disease Activity Assessment on Early Rheumatoid Arthritis Patients Treated Using a Treat to Target Strategy. Arthritis Care and Research, 2014, 66, 19-26.	3.4	52
53	Alopecia areata is characterized by dysregulation in systemic type 17 and type 2 cytokines, which may contribute to diseaseâ€associated psychological morbidity. British Journal of Dermatology, 2020, 182, 130-137.	1.5	52
54	Interleukin-18: a therapeutic target in rheumatoid arthritis?. Arthritis Research, 2005, 7, 38.	2.0	51

#	Article	IF	Citations
55	MicroRNA29a Treatment Improves Early Tendon Injury. Molecular Therapy, 2017, 25, 2415-2426.	8.2	51
56	Tyrosine kinase 2 and Janus kinaseâ€'signal transducer and activator of transcription signaling and inhibition in plaque psoriasis. Journal of the American Academy of Dermatology, 2022, 86, 148-157.	1.2	51
57	Psoriatic arthritis from a mechanistic perspective. Nature Reviews Rheumatology, 2022, 18, 311-325.	8.0	49
58	Efficacy and Safety of Guselkumab, an Interleukinâ€23p19â€"Specific Monoclonal Antibody, Through One Year in Biologicâ€Naive Patients With Psoriatic Arthritis. Arthritis and Rheumatology, 2021, 73, 604-616.	5.6	48
59	Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS). Annals of the Rheumatic Diseases, 2022, 81, 359-369.	0.9	47
60	Periodontitis in the absence of B cells and specific antiâ€bacterial antibody. Molecular Oral Microbiology, 2015, 30, 160-169.	2.7	46
61	Long-term study of the impact of methotrexate on serum cytokines and lymphocyte subsets in patients with active rheumatoid arthritis: correlation with pharmacokinetic measures. RMD Open, 2016, 2, e000287.	3.8	46
62	Molecular imaging of inflammation - Current and emerging technologies for diagnosis and treatment. , 2020, 211, 107550.		45
63	Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis. Rheumatology, 2021, 60, 2109-2121.	1.9	44
64	Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies. Annals of the Rheumatic Diseases, 2018, 77, 988-995.	0.9	41
65	GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis. Annals of the Rheumatic Diseases, 2020, 79, 490-498.	0.9	41
66	<scp>Longâ€Term</scp> Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukinâ€23, Through Twoâ€‰Years: Results From a Phase <scp>III</scp>, Randomized, <scp>Doubleâ€Blind</scp>, <scp>Placeboâ€Controlled</scp> Study Conducted in <scp>Biologicâ€Naive</scp> Patients With Active Psoriatic Arthritis. Arthritis and Rheumatology, 2022, 74, 475-485.	5.6	41
67	Elevated interleukin-10: A new cause of dyslipidemia leading to severe HDL deficiency. Journal of Clinical Lipidology, 2015, 9, 81-90.	1.5	38
68	EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19. Annals of the Rheumatic Diseases, 2021, 80, 698-706.	0.9	37
69	Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis. Journal of Comparative Effectiveness Research, 2018, 7, 1107-1123.	1.4	35
70	Targeting danger molecules in tendinopathy: the HMGB1/TLR4 axis. RMD Open, 2017, 3, e000456.	3.8	33
71	Single cell and spatial transcriptomics in human tendon disease indicate dysregulated immune homeostasis. Annals of the Rheumatic Diseases, 2021, 80, 1494-1497.	0.9	33
72	Small-molecule therapeutics in rheumatoid arthritis: Scientific rationale, efficacy and safety. Best Practice and Research in Clinical Rheumatology, 2014, 28, 605-624.	3.3	32

#	Article	IF	Citations
73	Ankylosing spondylitis patients display altered dendritic cell and T cell populations that implicate pathogenic roles for the IL-23 cytokine axis and intestinal inflammation. Rheumatology, 2016, 55, 120-132.	1.9	32
74	Urinary proteomics can define distinct diagnostic inflammatory arthritis subgroups. Scientific Reports, 2017, 7, 40473.	3.3	32
75	Wounds that heal and wounds that donâ€™t â^' The role of the IL-33/ST2 pathway in tissue repair and tumorigenesis. Seminars in Cell and Developmental Biology, 2017, 61, 41-50.	5.0	31
76	A review of JAKâ€“STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition. Rheumatology, 2022, 61, 1783-1794.	1.9	31
77	Ustekinumab Treatment and Improvement of Physical Function and Healthâ€Related Quality of Life in Patients With Psoriatic Arthritis. Arthritis Care and Research, 2016, 68, 1812-1822.	3.4	27
78	Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes. RMD Open, 2022, 8, e002074.	3.8	27
79	Visualising the interaction of CD4 T cells and DCs in the evolution of inflammatory arthritis. Annals of the Rheumatic Diseases, 2018, 77, 579-588.	0.9	26
80	2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19. Annals of the Rheumatic Diseases, 2022, 81, 34-40.	0.9	26
81	Mast Cells Contribute toPorphyromonas gingivalisâ€“induced Bone Loss. Journal of Dental Research, 2016, 95, 704-710.	5.2	25
82	A Cytomegalovirus Peptide-Specific Antibody Alters Natural Killer Cell Homeostasis and Is Shared in Several Autoimmune Diseases. Cell Host and Microbe, 2016, 19, 400-408.	11.0	25
83	Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2Âyears: results from the FUTURE 2 study. Arthritis Research and Therapy, 2018, 20, 113.	3.5	24
84	Abatacept Inhibition of T Cell Priming in Mice by Induction of a Unique Transcriptional Profile That Reduces Their Ability to Activate Antigenâ€Presenting Cells. Arthritis and Rheumatology, 2016, 68, 627-638.	5.6	23
85	Assessment of murine collagen-induced arthritis by longitudinal non-invasive duplexed molecular optical imaging. Rheumatology, 2016, 55, kev361.	1.9	22
86	The Scottish Early Rheumatoid Arthritis (SERA) Study: an inception cohort and biobank. BMC Musculoskeletal Disorders, 2016, 17, 461.	1.9	22
87	Long-term outcomes following severe COVID-19 infection: a propensity matched cohort study. BMJ Open Respiratory Research, 2021, 8, e001080.	3.0	21
88	Effect of IL-6 receptor blockade on high-sensitivity troponin T and NT-proBNP in rheumatoid arthritis. Atherosclerosis, 2016, 254, 167-171.	0.8	20
89	Model answers: Rational application of murine models in arthritis research. European Journal of Immunology, 2018, 48, 32-38.	2.9	19
90	Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials. RMD Open, 2021, 7, e001679.	3.8	19

#	Article	IF	Citations
91	The atypical chemokine receptor ACKR2 suppresses Th17 responses to protein autoantigens. Immunology and Cell Biology, 2015, 93, 167-176.	2.3	18
92	Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies. Rheumatology, 2021, 60, 5337-5350.	1.9	18
93	Translational targeting of inflammation and fibrosis in frozen shoulder: Molecular dissection of the T cell/IL-17A axis. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	18
94	Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing Spondylitis. Journal of Rheumatology, 2020, 47, 539-547.	2.0	16
95	Attenuation of Dupuytrenâ€™s fibrosis via targeting of the STAT1 modulated IL-13RÎ±1 response. Science Advances, 2020, 6, eaaz8272.	10.3	16
96	In Human Autoimmunity, a Substantial Component of the B Cell Repertoire Consists of Polyclonal, Barely Mutated IgG+ve B Cells. Frontiers in Immunology, 2020, 11, 395.	4.8	16
97	The active metabolite of spleen tyrosine kinase inhibitor fostamatinib abrogates the CD4+ T cell-priming capacity of dendritic cells. Rheumatology, 2015, 54, 169-177.	1.9	15
98	Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritis. Journal of Comparative Effectiveness Research, 2019, 8, 497-510.	1.4	15
99	Cellular imaging in rheumatic diseases. Nature Reviews Rheumatology, 2015, 11, 357-367.	8.0	14
100	The IL-23/IL-17A axis in spondyloarthritis: therapeutics informing pathogenesis?. Current Opinion in Rheumatology, 2020, 32, 349-356.	4.3	14
101	Responsiveness of Serum Câ€Reactive Protein, Interleukinâ€17A, and Interleukinâ€17F Levels to Ustekinumab in Psoriatic Arthritis: Lessons From Two Phase III, Multicenter, Doubleâ€Blind, Placeboâ€Controlled Trials. Arthritis and Rheumatology, 2019, 71, 1660-1669.	5.6	13
102	Does Age Matter in Psoriatic Arthritis? A Narrative Review. Journal of Rheumatology, 2022, 49, 1085-1091.	2.0	13
103	Association Between Enthesitis and Health-related Quality of Life in Psoriatic Arthritis in Biologic-naive Patients from 2 Phase III Ustekinumab Trials. Journal of Rheumatology, 2019, 46, 1458-1461.	2.0	11
104	Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis. RMD Open, 2021, 7, e001845.	3.8	11
105	Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies. RMD Open, 2022, 8, e002195.	3.8	11
106	Effect of Secukinumab on the Different GRAPPA-OMERACT Core Domains in Psoriatic Arthritis: A Pooled Analysis of 2049 Patients. Journal of Rheumatology, 2020, 47, 854-864.	2.0	10
107	Psoriatic arthritis: embracing pathogenetic and clinical heterogeneity?. Clinical and Experimental Rheumatology, 2016, 34, 9-11.	0.8	10
108	Elevated ACKR2 expression is a common feature of inflammatory arthropathies. Rheumatology, 2017, 56, 1607-1617.	1.9	9

#	Article	IF	Citations
109	IL-23 orchestrating immune cell activation in arthritis. Rheumatology, 2021, 60, iv4-iv15.	1.9	9
110	Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials. RMD Open, 2022, 8, e002049.	3.8	8
111	Arthritis in space and time â€“ To boldly go!. FEBS Letters, 2011, 585, 3640-3648.	2.8	5
112	Immunoglobulin A antibodies to oxidized collagen type II as a potential biomarker for the stratification of spondyloarthritis from rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2020, 49, 281-291.	1.1	5
113	Stromal â€œactivationâ€•markers do not confer pathogenic activity in tendinopathy. Translational Sports Medicine, 2021, 4, 268-279.	1.1	5
114	Association of Cardiac Biomarkers With Cardiovascular Outcomes in Patients With Psoriatic Arthritis and Psoriasis: A Longitudinal Cohort Study. Arthritis and Rheumatology, 2022, 74, 1184-1192.	5.6	5
115	The extending scope of kinase inhibition in immune diseases. Lancet, The, 2018, 392, 2328-2331.	13.7	2
116	Limits of traditional evidence-based medicine methodologies exemplified by the novel era in psoriatic arthritis drug development. Expert Review of Clinical Immunology, 2019, 15, 441-444.	3.0	2
117	Dissecting the molecular control of immune cell accumulation in the inflamed joint. JCI Insight, 2022, 7, .	5.0	2
118	Does practice mirror the evidence base in the treatment of rheumatoid arthritis?. Clinical Rheumatology, 2009, 28, 961-970.	2.2	1
119	OP0272â€…Abatacept is highly effective in inhibiting T cell priming but fails to induce T cell tolerance after primary antigen encounter. Annals of the Rheumatic Diseases, 2013, 71, 148.2-148.	0.9	1
120	P059â€…Ex vivo comparison of baricitinib, upadacitinib, filgotinib and tofacitinib for cytokine signalling in human leukocyte subpopulations. , 2018, , .		1
121	P174â€ƒUpadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC. Rheumatology, 2021, 60, .	1.9	1
122	A Vision for Cytokine Biology with 20/20 Clarity. Function, 2020, 2, zqaa042.	2.3	1
123	Articular and Extra-Articular Benefits in ACR20 Non-responders at Week 104 Treated With Apremilast: Pooled Analysis of Three Randomized Controlled Trials. Rheumatology and Therapy, 2021, 8, 1677-1691.	2.3	1
124	Breach of self tolerance in rheumatoid arthritis: a role for Th17 effector T cells?. Annals of the Rheumatic Diseases, 2011, 70, A50-A50.	0.9	0
125	OP0008â€…Synovial Fibroblast Proliferation Is Enhanced by Microrna-223 Delivery through Monocyte-Derived Microparticles. Annals of the Rheumatic Diseases, 2016, 75, 55.3-56.	0.9	0
126	A10.07â€…The kinetic cytokine/chemokine secretory profile in surgical models of osteoarthritis. Annals of the Rheumatic Diseases, 2016, 75, A75.2-A75.	0.9	0

#	Article	IF	Citations
127	A1.10â€…The GM-CSF/CCL17 axis in the rheumatoid synovial environment. Annals of the Rheumatic Diseases, 2016, 75, A4.2-A5.	0.9	0
128	FRI0051â€…In Vivo Imaging To Characterise The Specificity, Function and Behavior of The CD4+ T Cells Initiating Articular Inflammation. Annals of the Rheumatic Diseases, 2016, 75, 444.2-444.	0.9	0
129	RHEUMATOID ARTHRITIS: PATHOGENESIS204.â€ƒCHARACTERIZATION OF SYNOVIUM TISSUES MACROPHAGE OF RHEUMATOID ARTHRITIS PATIENTS. Rheumatology, 2017, 56, .	1.9	0
130	P173â€ƒEfficacy and safety of upadacitinib versus placebo and adalimumab in patients with active PsA and inadequate response to non-biologic DMARDs (SELECT-PSA-1): a double-blind, randomised controlled phase III trial. Rheumatology, 2021, 60, .	1.9	0
131	Tofacitinib inhibits CD4 T cell polarisation to Th1 during priming thereby leading to clinical impact in a model of experimental arthritis. Clinical and Experimental Rheumatology, 2021, , .	0.8	0
132	Tofacitinib inhibits CD4 T cell polarisation to Th1 during priming thereby leading to clinical impact in a model of experimental arthritis. Clinical and Experimental Rheumatology, 0, , .	0.8	0
133	OA36â€ƒBimekizumab in patients with psoriatic arthritis: achievement and maintenance of Psoriatic Arthritis Response Criteria responses through 3 years in a phase 2b open-label extension study. Rheumatology, 2022, 61, .	1.9	0
134	Levelling the playing field of RMD research across Europe to address patientsâ€™ needs: the emerging EULAR Research Centre. RMD Open, 2022, 8, e002456.	3.8	0